Common osteoporosis drug slows formation of new bone

Although the drug zoledronic acid slows bone loss in osteoporosis patients, it also boosts levels of a biomarker that stops bone formation, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

Osteoporosis weakens bones and increases the risk patients will suffer fractures. The findings suggest combination therapy may be a more effective approach to battling this common condition.

"The key to effectively treating osteoporosis lies in increasing bone mass," said the study's lead author, Antonino Catalano, MD, PhD, of the University of Messina in Italy. " halts , but it also signals the body to stop forming new bone mass. The drug may need to be combined with other treatments to add bone mass."

The prospective intervention study followed the treatment of 40 postmenopausal women at an ambulatory care center. Half of the women received zoledronic acid, and half received a placebo. Levels of sclerostin – a that inhibits – increased among the participants who were treated with zoledronic acid.

"The data points to an opportunity to increase bone mass by combining zoledronic acid with a drug that suppresses the resulting sclerostin's effect," Catalano said. "An innovative combination therapy using zoledronic acid and selective antibodies to block the sclerostin could simultaneously stop bone loss and encourage new bone formation. This is an important avenue for researchers to explore as they develop new osteoporosis treatments."

More information: The article, "Zoledronic Acid Acutely Increases Sclerostin Serum Levels in Women with Postmenopausal Osteoporosis," appears in the May 2013 issue of JCEM.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

9 hours ago

The nation's largest pharmacy benefits manager is throwing its weight into the fight over high-cost hepatitis C drugs with a coverage restriction that might ultimately lower prices and improve patient access ...

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.